The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)-directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001).
 
Jesus Corral Jaime
No Relationships to Disclose
 
Kartik Sehgal
Honoraria - Academy for Continued Healthcare Learning; AmerisourceBergen; Binacea; Medscape; Pri-Med
Consulting or Advisory Role - Dr. Reddy's Laboratories; Equinox Group; Exelixis; Fore Biotherapeutics; Guidepoint Global; Medscape; Pfizer; Scholar Rock
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Binacea; Merck; Pfizer; Pri-Med
 
Javier David Benitez Fuentes
No Relationships to Disclose
 
Muh-Hwa Yang
No Relationships to Disclose
 
Joseph Ye
Employment - Vista Oncology, AON
Leadership - Vista Oncology, AON
Stock and Other Ownership Interests - AON
Honoraria - AstraZeneca; Incyte
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca; Henlius; Johnson & Johnson; Pfizer
Travel, Accommodations, Expenses - Henlius
 
Ed Kingsley
No Relationships to Disclose
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bayer; BeOne; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Apollo (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); Pyxis (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Michael Mark
Consulting or Advisory Role - AstraZeneca; bms; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; PharmaMar; Roche
Research Funding - Gilead Sciences (Inst); Swiss Cancer Research Foundation (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen (Inst); Merck (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Foundation Medicine (Inst); GlaxoSmithKline; Illumina (Inst); Imedex (Inst); Incyte (Inst); Ipsen (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Biocartis (Inst); Bioinvent (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Illumina (Inst); Incyte (Inst); Ipsen (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Nuvation Bio (Inst); Nykode Therapeutics (Inst); Nykode Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Promontory Therapeutics (Inst); Qlucore (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Zymeworks (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MJH Life Sciences; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology; ESMO; ESMO Open Associate Editor; ETOP Scientific chair; JTO Past Deputy Editor; Oncosuisse President; SAMO President; Swiss Cancer League Vice-President
 
Francesca Toffalorio
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Tianhua Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Sona Ghorashi
Stock and Other Ownership Interests - Microbot Medical; Microbot Medical (I)
Honoraria - Boston Scientific (I); Guerbet (I); Medtronic (I)
Consulting or Advisory Role - Boston Scientific (I); Medtronic (I)
Speakers' Bureau - Boston Scientific (I); Medtronic (I)
Research Funding - Guerbet (I)
Patents, Royalties, Other Intellectual Property - University of Maryland, College Park (I)
Travel, Accommodations, Expenses - Boston Scientific (I); Guerbet (I); Medtronic (I)
 
Anthony Lee
Employment - Pfizer; Roche/Genentech; Seagen
Stock and Other Ownership Interests - Pfizer; Roche/Genentech; Seagen
Patents, Royalties, Other Intellectual Property - U.S. Provisional Patent Application No. 17/159,128 Title: Methods for treatment of cancer with an ANTI-TIGIT antagonist antibody
 
Steven Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Speakers' Bureau - Alkermes (Inst)
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Incyte (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sensei Biotherapeutics (Inst); Sorrento Therapeutics (Inst); Takeda (Inst); Vyriad (Inst)